Resmed INC

ResMed Inc. announced an agreement to sell its MatrixCare business to Frazier Healthcare Partners for $490 million in an all-cash transaction, aiming to sharpen its focus on sleep and connected care markets.

ResMed reported strong third-quarter fiscal 2026 results with 11% revenue growth and significant margin expansion.

ResMed Inc. announced robust second-quarter fiscal year 2026 results, with revenue up 11% and non-GAAP diluted EPS increasing by 16%, alongside a declared quarterly cash dividend of $0.60 per share.

ResMed Inc. announced board changes and stockholder approval of amendments to its 2009 Incentive Award Plan and 2018 Employee Stock Purchase Plan, increasing share reserves for employee compensation.

ResMed Inc. reports a strong start to fiscal year 2026 with a 9% revenue increase and significant gross margin expansion, alongside a declared quarterly dividend.

ResMed Inc. announced the election of Nicole Mowad-Nassar to its board of directors and the upcoming retirement of long-serving board member Richard Sulpizio.

ResMed Inc. announced robust first-quarter fiscal year 2026 results, with net revenue up 9% and diluted earnings per share increasing by 12%, driven by strong demand in Sleep and Breathing Health products and improved gross margins.

ResMed Inc. announces an 8% increase in net revenue for the third quarter of fiscal year 2025, driven by strong performance in both Sleep and Breathing Health and Residential Care Software segments.

ResMed Inc. announces a 10% increase in net revenue for the quarter ended December 31, 2024, fueled by strong performance in Sleep and Breathing Health and Residential Care Software segments.

ResMed Inc. announced a robust first quarter for fiscal year 2025, with significant revenue growth and improved profitability.

ResMed Inc. announced a 7% increase in revenue for the third quarter of 2024, alongside improved gross margins and diluted earnings per share.

ResMed Inc. saw a 12% increase in revenue for the quarter ended December 31, 2023, driven by growth in both its Sleep and Respiratory Care products and Software as a Service (SaaS) segments.

ResMed Inc. announced a robust fiscal year 2025, with significant revenue and profit increases driven by its digital health and sleep & breathing solutions.

ResMed Inc. released its annual report for fiscal year 2024, showcasing a robust 11% increase in net revenue and significant growth across its Sleep and Respiratory Care and Software as a Service (SaaS) segments.

ResMed CEO Michael Farrell executed a series of transactions involving the acquisition and disposition of company stock under a pre-arranged Rule 10b5-1 trading plan.

ResMed Inc. Chairman and CEO Michael J. Farrell reported the sale of 4,991 shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

ResMed's Global General Counsel, Michael J. Rider, reported a disposition of company stock for tax withholding purposes related to vested Restricted Stock Units.

ResMed Inc. Chairman and CEO Michael Farrell reported transactions involving company stock, including acquisitions and dispositions, executed under a pre-arranged Rule 10b5-1 trading plan.

ResMed Inc. Chief Financial Officer Brett Sandercock has officially retired from his position effective May 4, 2026.

ResMed Chairman and CEO Michael Farrell executed a Rule 10b5-1 trading plan, acquiring 4,991 shares and selling 4,991 shares.

ResMed Inc. announces its 2025 Annual Meeting of Stockholders, outlining proposals including director elections, auditor ratification, executive compensation, and incentive plan amendments.

ResMed reports strong fiscal year 2025 financial performance, driven by innovation and digital health expansion, while proposing key governance updates and board changes.

ResMed Inc. issues an amendment to its proxy statement to correct a scrivener's error in the Notice of Annual Meeting of Stockholders regarding the telephone number for voting and the website address for accessing the proxy statement and annual report.

ResMed Inc. will hold its annual meeting on November 20, 2024, to vote on the election of directors, ratification of the auditor, and executive compensation.

ResMed's proxy statement outlines the company's fiscal 2024 highlights, strategic initiatives, and executive compensation, focusing on long-term value creation and stakeholder engagement.

ResMed Inc. has filed a Schedule 13G, reporting beneficial ownership of 1,943,828 ordinary shares in Nyxoah SA, representing 1.95% of the outstanding shares.

Vanguard Portfolio Management has reported beneficial ownership of 7,886,489 shares, representing 5.41% of ResMed Inc.'s common stock, as of March 31, 2026.

Vanguard Capital Management has reported beneficial ownership of 11,961,706 shares, representing 8.2% of ResMed Inc.'s common stock as of March 31, 2026.

The Vanguard Group has filed an amended Schedule 13G, reporting zero beneficial ownership in ResMed Inc. following an internal realignment.

The Vanguard Group has filed an amendment to its Schedule 13G, reporting a beneficial ownership of 13.66% in ResMed Inc. as of September 30, 2025.